Breakouts HappenBH
Ticker⌘K
Closed
This is a preview. Unlock full access to all scanners and features. $8/month →
BMY stock

BMY - Bristol-Myers Squibb Stock Price, Chart, News and Analysis

-- --
OPEN--
HIGH--
LOW--
PREV CLOSE--
52W HIGH--
52W LOW--
Sector Healthcare Industry Drug Manufacturers - General Next earnings Oct 29, 2026 55 days
Featured today in these scanners:
Market Cap$136.0B
RS Score18.53
RSI67.0
ADX49.6
Vol Ratio0.74x
Dist MA200+16.80%
5D+1.29%
1M+5.87%
3M+18.89%
6M+12.72%
52W+45.09%
Above MA50 / MA200Yes / Yes

Bristol-Myers Squibb Company Common Stock (BMY): What does the company do?

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Unlock full access

Every scanner, the BH Indicator, insider and options flow, sector and industry rankings, the themes, the trading journal and the daily briefings from the Senior Analyst.

See plans →
Disclaimer

Breakouts Happen publishes market analysis and screening tools. Every idea, opinion and forecast on this site — stated or implied — is provided for informational purposes only and is not a recommendation to invest, trade or speculate in any market. Any position taken in light of the material published here is taken at your own risk, financial or otherwise. Breakouts Happen is not a registered investment advisor, and nothing on this site is an offer or solicitation to buy or sell any security.

Market data is delayed and provided for reference only. Past performance does not indicate future results.

© 2026 Breakouts Happen. All Rights Reserved. +SCAOPN Market data delayed.
ESC
Type to search stocks, ETFs, indices
We value your privacy
We use cookies to enhance your browsing experience and analyze our traffic. By clicking “Accept all”, you consent to our use of cookies. Learn more
Preference centre
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information is mostly used to make the site work as you expect it to.
Necessary3 cookies Always active

Essential cookies for basic site functions, including your session.

Functional4 cookies

Cookies for enhanced functionality, such as your theme preference.

Analytics3 cookies

Cookies to understand site usage and improve our service.

Performance1 cookie

Cookies to improve site performance.